非小细胞肺癌全切术后治疗方案的临床决策研究
|
摘要
目的 根据检索和搜集到的有关非小细胞肺癌的资料，探讨非小细胞肺癌全切除术后各种治疗方案的效果及其优选方案，为临床医务人员提供治疗方案的决策参考，为临床决策提供分析的框架和思路。
方法 对有关非小细胞肺癌的检索资料进行Meta分析，初步判断非小细胞肺癌全切除术后各治疗方案的效果。结合Meta分析，综合考虑治疗成本和收益，建立决策树模型，进行成本-效果分析和成本-效用分析，探讨非小细胞肺癌全切除术后各种治疗方案中的优选方案，并用敏感性分析检查“最优”方案的稳定性。
结果 非小细胞肺癌全切除术后治疗方案的Meta分析结果表明，含铂化疗比观察更有效，放疗效果不及观察，化放疗与放疗效果无差异。成本-效果分析和成本-效用分析决策树模型的分析结果均显示，观察、化疗、放疗、化放疗四种方案中观察方案是优选方案，化疗是次选方案。敏感性分析结果进一步验证了决策分析优选方案的稳定性。
Objectives
Based on the data of non-small cell lung cancer and its regimens collected from literatures, this study was to explore and discuss the effect of different regimens after complete resection of non-small cell lung cancer to make reference of regimen for medical professional and offer a route and technique of clinical decision-making analysis.
Methods
Meta analysis was used to get the effectiveness of different regimens after complete resection of non-small cell lung cancer. Decision tree model of cost-effectiveness analysis and cost-utility analysis were employed by using the results of meta analysis, and in decision tree model, therapeutic cost, effectiveness and utility were taken into account. Furthermore, sensitivity analysis was used to test the stability of results of decision-making analysis.
方法 对有关非小细胞肺癌的检索资料进行Meta分析，初步判断非小细胞肺癌全切除术后各治疗方案的效果。结合Meta分析，综合考虑治疗成本和收益，建立决策树模型，进行成本-效果分析和成本-效用分析，探讨非小细胞肺癌全切除术后各种治疗方案中的优选方案，并用敏感性分析检查“最优”方案的稳定性。
结果 非小细胞肺癌全切除术后治疗方案的Meta分析结果表明，含铂化疗比观察更有效，放疗效果不及观察，化放疗与放疗效果无差异。成本-效果分析和成本-效用分析决策树模型的分析结果均显示，观察、化疗、放疗、化放疗四种方案中观察方案是优选方案，化疗是次选方案。敏感性分析结果进一步验证了决策分析优选方案的稳定性。
Objectives
Based on the data of non-small cell lung cancer and its regimens collected from literatures, this study was to explore and discuss the effect of different regimens after complete resection of non-small cell lung cancer to make reference of regimen for medical professional and offer a route and technique of clinical decision-making analysis.
Methods
Meta analysis was used to get the effectiveness of different regimens after complete resection of non-small cell lung cancer. Decision tree model of cost-effectiveness analysis and cost-utility analysis were employed by using the results of meta analysis, and in decision tree model, therapeutic cost, effectiveness and utility were taken into account. Furthermore, sensitivity analysis was used to test the stability of results of decision-making analysis.
引文
1．席酉民．管理研究．机械工业出版社，2000；328-339．
2．隆瑞．哈佛商学院管理法则全书．中国对外翻译出版公司，2001；4(2)：2004-2029．
3. Jerome P. Kassirer, Alan J Moskiwitz, Joseph Lau, etal. Decision analysis: a progress report. Annals of international medicine, 1987; 106(2): 275-291.
4．张大庆．临床决策：医学哲学研究的一个重要领域．医学与哲学，2004；25(12)：17-20．
5. EDDY, DM. Clinical Decision Making. Boston: Joncs and Bardctt Publishers, 1996.
6．李幼平 主编．循证医学．高等教育出版社，2003．
7. Munehisa Imaizumi and Study Group of Adjuvant Chemotherapy for Lung Cancer (Chub Japan). Postoperative adjuvant cisplatin, vindesin, plusuracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer. Lung Cancer, 2005; 49(1): 85-94.
8. Niiranen A, Niitamo-Korhonen S, Kouri M, et al. Adjuvant chemotherapy after radical surgery for non-small-cell lung cancer: a randomized study. J Clin Oncol, 1992; 10: 1927-1932.
9. Ohta M, Tsuchiya R, Shimoyama M, et al. Adjuvant chemotherapy for completely resected stage Ⅲ non-small cell lung cancer. Results of a randomized prospective study. J Thorac Cardiovasc Surg, 1993; 106(4): 703-708.
10. The Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan). A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study). Eur J Surg Oncol, 1995; 21(1): 69-77.
11. West Japan Study Group for lung cancer surgery (WJSG). Postoperative adjuvant chemotherapy with PVM (Cisplatin+Vindesine+Mitomycin C) and UFT (Uracil+Tegaful) in resected stage Ⅰ-Ⅱ NSCLC (non-small cell lung cancer): a randomized clinical trial. Eur J Cardiothorac Surg, 1999; 15(4): 438-443.
12. Xu G, Rong T, Lin P.Adjuvant chemotherapy following radical surgery for non-small-cell lung cancer: a randomized study on 70 patients. Chin Med J (Engl), 2000; 113(7): 617-620.
13. Mineo TC, Ambrogi V, Corsaro V, et al. Postoperative adjuvant therapy for stage IB non-small-cell lung cancer. Eur J Cardiothorac Surg, 2001; 20(2): 378-884.
14. Tada H, Tsuchiya R, Ichinose Y, et al. Randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304). Lung Cancer, 2004; 43(2): 167-173.
15. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med, 2005; 352(25): 2589-2597.
16. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cance: a Meta-analysis using updated data on individual patients from 52 randomised clinical trials.BMJ.1995; 311: 899-909.
17. Katsuyuki Hotta, Keitaro Matsuo, Hiroshi Ueoka, et al. Role of Adjuvant Chemotherapy in Patients With Resected Non-Small-Cell Lung Cancer: Reappraisal With a Meta-Analysis of Randomized Controlled Trials. J Clin Oncol, 22(19); 2004: 3860-3867.
18．廖日强，吴一龙，杨学宁等．非小细胞肺癌完全切除术后含铂辅助化疗方案累积Meta分析．循证医学，2003；3(4)：196-203．
19. Van Houtte P, Rocmans P, Smets P, et al. Postoperative radiation therapy in lung caner: a controlled trial after resection of curative design. Int J Radiat Oncol Biol Phys, 1980; 6(8): 983-986.
20. Weisenburger TH. Effects of postoperative mediastinal radiation on completely resected stage Ⅱ and stage Ⅲ epidermoid cancer of the lung. LCSG 773.Chest, 1994; 106(6 Suppl): 297S-301S.
21. Debevec M, Bitenc M, Vidmar S, et al. Postoperative radiotherapy for radically resected N2 non-small-cell lung cancer (NSCLC): randomised clinical study 1988-1992. Lung Cancer, 1996; 14(1): 99-107.
22. Lafitte JJ, Ribet ME, Prevost BM, et al. Postresection irradiation for T2 NO MO non-small cell carcinoma: a prospective, randomized study. Ann Thorac Surg, 1996; 62(3): 830-834.
23. Stephens RJ, Girling DJ, Bleehen NM, et al. Amulticentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Br J Cancer, 1996; 74(4): 632-639.
24. Dautzenberg B, Arriagada R, Chammard AB, et al. A controlled study of postoperative radiotherapy for patients with completely resected non-small cell lung carcinoma. Groupe d'Etude et de Traitement des Cancers Bronchiques. Cancer, 1999; 86(2): 265-273.
25. Feng QF, Wang M, Wang LJ, et al. A study of postoperative radiotherapy in patients with non-small-cell lung cancer: a randomized trial. J Radiat Oncol Biol Phys, 2000; 47(4): 925-9.
26．曹卡加，黄惠英，练小荷，崔念基．Ⅲa(N2)期非小细胞肺癌术后放疗的疗效评价．癌症，2001，20(3)：305-307．
27．姚波，周大明，程玉龙等．非小细胞肺癌术后放疗的临床意义．黑龙江医学，2001， 25(11)：808-809．
28. Trodella L, Granone P, Valente S, et al. Adjuvant radiotherapy in non-small cell lung cancer with pathological stage Ⅰ: definitive results of a phase Ⅲ randomized trial. Radiother Oncol, 2002; 62(1): 11-29.
29．曹卡加，黄惠英，练小荷等．术后放射治疗对非小细胞肺癌疗 效的影响．中国肿瘤,2003；30(9)：642—644．
30. PORT Meta-analysis Trialists Group.Postoperative radiotherapy in non-small-cell lung cancer: systematic review and Meta-analysis of individual patient data from nine randomised controlled trials. Lancet, 1998; 352(9124): 257-263.
31. Burdett S, Stewart L; on behalf of the PORT Meta-analysis Group. Postoperative radiotherapy in non-small-cell lung cancer: update of an individual patient data Meta-analysis. Lung Cancer. 2005 Jan; 47(1): 81-83.
32. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst, 1996 Sep 4; 88(17): 1210-1215.
33. Dautzenberg B, Chastang C, Arriagada R, et al. Adjuvant radiotherapy versus combined sequential chemotherapy followed by radiotherapy in the treatment of resected nonsmall cell lung carcinoma. A randomized trial of 267 patients. GETCB (Groupe d'Etude et de Traitement des Cancers Bronchiques). Cancer, 1995 Sep 1; 76(5): 779-786.
34. Steven M. Keller, M.D., SudeshnaAdak, Ph.D. et al. for The Eastern Cooperative Oncology Group.ARandomized Trial of Postoperative Adjuvant Therapy in Patients with Completely Resected Stage II or IIIa Non-Small-Cell Lung Cancer. J Clin Oncol, 2000; 343(17): 1217-1222.
35. Lad T. The comparison of CAP chemotherapy and radiotherapy to radiotherapy alone for resected lung cancer with positive margin or involved highest sampled para- tracheal node (stage IIIA). LCSG 791. Chest, 1994 Dec; 106(6 Suppl): 302S-306S.
36. Ovac V, Smrdel U, Institute of Oncology. Meta-analyses of clinical trials in patients with non-small cell lung cancer. Neoplasm, 2004; 51(5): 334-340.
37. Maurizio Tonato. Final report of the (ALPI)-an Italian/ EORTC-LCG randomized trial of adjuvant chemotherapy in completely resected non-small cell lung cancer(NSCLC). Annals of Oncology, 13(Suppl.5): 9.
38. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage Ⅰ, Ⅱ, or Ⅲa non-small-cell lung cancer. J Natl Cancer Inst, 2003; 95: 1453-1461.
39．吴一龙，杨学宁，杨衿记等．2002年临床肿瘤学重要文献解读．循证医学，2003；3(1)：7-14．
40．钱正子，王华庆．Ⅰb-Ⅲa期非小细胞肺癌术后辅助化疗的进展．中国肿瘤临床，2004；31(24)：1428-1430。
41. ASCO 2003 annual Chicago: Chemotherapy improves survival after lung cancer surgery.
42．陆舜．非小细胞肺癌综合．中国癌症杂志，2005；8(1)：74-76．
43. Strauss G, Herndon J, Maddaus M, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage 1B non-small cell lung cancer(NSCLC): Report of Cancer and Leukemia Group B (CALGB)Protocol 9633. Proc Am Soc Clin Oncol, 2004; 23(supp1): 7019a.
44. Winton T, Livingston R, Johnson D, et al. A prospective randomized trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely rezected stage Ⅰ B and Ⅱ non-smsll cell lung cancer(NSCLC) Intergroup JBR. Proc Am Soc Clin Oncol, 2004; 23(supp10): 7018a.
45．韩宝惠．早期非小细胞肺癌多学科治疗的争议．循证医学，2003；3(2)：68-69．
46．夏佳，李晓松．非小细胞肺癌完全切除术后含铂辅助化疗效果的Meta分析．中国循证医学杂志，2005；5(12)：936-940．
47．傅小龙．放疗在非小细胞肺癌治疗中地位和研究进展．中国癌症杂志，2005；15(3)：217-223．
48．姜丽萍，瞿佳．循证医学在眼视光学的应用(Ⅲ)临床决策分析． 眼视光学杂志，2002；4(3)：185-186．
49．吴久鸿，刘国恩．药物经济学在我国的发展现状及应用．中国药物应用与监测，2005；1：1-4．
50．文朝阳，洪明晃．临床科学研究-设计、测量、评价．生存质量的测量与评价第2版，中山大学出版社，2002：62-77．
51．谢忠，潘达超，廖思海等．干扰素甲地孕图配合EP方案与单纯E防案治疗晚期非小细胞肺癌的对比研究．癌症，2000；19(4)： 370-373．
52．刘志涛，祁秉先，姜润生．成本效用分析原则及方法初探．卫生软科学，2003；17(5)：36-37．
53．陈民，李孜，何强等．肾替代治疗初期的成本-效用分析．中国循证医学杂志 2004，4(7)：453-459．
54. Desch CE, Lasala MR, Smith TJ, et al. The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse. J Clin Oncol, 1992Feb; 10(2): 200-209.
55. Wilcox GM, Beck JR. Early invasive cancer in adenomatous colonic polyps ("malignant polyps"). Evaluation of the therapeutic options by decision analysis.Gastroenterology, 1987 May; 92: 1159-1168.
56. Plante DA, Piccirillo JF, Sofferman RA. Decision analysis of treatment options in pyriform sinus carcinoma. Med Decis Making, 1987A; 7(2): 74-83.
57. Velanovich V. Choice of treatment for stage 1 floor-of-mouth cancer. A decision analysis. Arch Otolaryngol Head Neck Surg, 1990; 116: 951-956.
58. MD Brundage, PA Groome, D Feldman-Stewart, et al. Decision analysis in locally advanced non-small cell lung cancer: is it useful? J Clin Oncol, 1997: 873-883.
59. Hillner BE, Smith TJ. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med, 1991; 324(3): 160-168.
60. Fleming C, Wasson JH, Albertsen PC, et al. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. JAMA, 1993 26; 269(20): 2650-2658.
61. Mold JW, Holtgrave DR, Bisonni RS, et al. The evaluation and treatment of men with asymptomatic prostate nodules in primary care: a decision analysis.J Fam Pract, 1992; 34(5): 561-568.
62．朱彩蓉．糖尿病治疗效果的药物经济学研究．四川大学博士学位论文．2004．
63．陈洁．药物经济．成都科技大学出版社，2000．
64．孙利华．药物经济学与新药研究发展．化学工业出版社，2003．
65．张新平．测量健康状况的新指标-QALYs．国外医学社会医学分册，1997；14(1)：22-24．
66．熊敏，吴一龙 主编．现代肺癌病理与临床．科学出版社．2003．
67．杨学宁，廖日强，吴一龙等．NCCN非小细胞肺癌临床指引2004/2005版更新．循证医学，2004；4(4)：252-256．
68．于琳 整理．2004中国肺癌高峰论坛访谈．循证医学．2004，4(2)：125-128．
69. Jeffrey B, Rubins. The progress of therapy with Non-small cell lung cancer. J Respir Dis, 2003; 24(7): 315-321.
70．许小幸，李定国，蔡全才等．肠易激综合征病人生活质量及其影响因素分析．青岛大学医学院学报，2005；41(2)：151-153．
71．孙晓花，刘爱忠．应用Markov模型进行临床决策分析的思考．医学与哲学，2004；25(8)：8-9．
1．席酉民．管理研究．机械工业出版社，2000：328-339．
2．隆瑞．哈佛商学院管理法则全书．中国对外翻译出版公司，2001：2004-2029．
3．陈铤．决策分析．科技出版社，1987．
4．刘文龙，高爱厚．经济决策分析．军事谊文出版社，1993．
5．姜青舫．实用决策分析．贵州人民出版社，1988．
6．张斌等．市场预测与决策．电子科技大学出版社，1996．
7. Jerome P. Kassirer, Alan J Moskiwitz, Joseph Lau, et al. Decision analysis: a progress report. Annals of international medicine, 1987; 106(2): 275-291.
8．张大庆．临床决策：医学哲学研究的一个重要领域．医学与哲学，2004；25(12)：17-20．
9. Eddy DM. Clinical Decision Making. Boston: Joncs and Bardctt Publishers. 1996.
10．李幼平 主编．循证医学．高等教育出版社．2003．
11．姜丽萍，瞿佳．循证医学在眼视光学的应用(Ⅲ)临床决策分析．眼视光学杂志，2002；4(3)：185-186．
12．史宗道．循证医学与临床决策分析．辽宁医学杂志，2001；15(5)： 229-233．
13．《默克诊疗手册》第二十一章，特殊医学．第295节．临床决策．用Bayes定理修正概率．
14．顾维正，马静波，杨滔波等．临床甲状腺功能检查新策略的医学决策学方法初步探讨．科技通报，1995；11(6)：375-380．
15．孙晓花，刘爱忠．应用Markov模型进行临床决策分析的思考．医学与哲学， 2004；25(8)：8-9，20．
16．王倩．应用Markov模型进行临床决策分析．《国外医学》卫生经济分册，2000；17(2)：89-90．
17. Hillner BE, Smith TJ. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med, 1991; 324(3): 160-8.
18. Fleming C, Wasson JH, Albertsen PC, et aI. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. JAMA, 1993; 269(20): 2650-2658.
19. Mold JW, Holtgrave DR, Bisonni RS, et al. The evaluation and treatment of men with asymptomatic prostate nodules in primary care: a decision analysis. J Fam Pract, 1992; 34(5): 561-568.
20．徐凌中，柳丽华，王永杰．效用指标的测量方法及其研究进展．国外医学卫生经济分册，2001；18(2)：88-92．
21．朱彩蓉．糖尿病治疗效果的药物经济学研究．四川大学博士学位论文．2004．
22．陈洁．药物经济．成都科技大学出版社，2000．
23．孙利华．药物经济学与新药研究发展．化学工业出版社，2003．
24．吴久鸿，刘国恩．药物经济学在我国的发展现状及应用前．中国药物应用与监测，2005；1：1-4．
25．文朝阳．生存质量的测量与评价．临床科学研究-设计、测量、评价冲山大学出版社，2002：62-77．
26．杨宁德，李凌江，陈晋东．生活质量评估外科手术医师临床决策的新思考．当代医师杂志，1998；3(9)：47-49．
27．杨朋，吴一龙，谷力加．评估肺癌患者生活质量的方法学．循证医学，2002；2(2)：105-107．
28．王卫华，卢祖洵．生命质量研究的现状与趋势．医学与社会，2005； 18(7)： 8-10．
29．谢忠，潘达超，廖思海等．干扰素甲地孕图配合EP方案与单纯E防案治疗晚期非小细胞肺癌的对比研究．癌症，2000； 19(4)：370-373．
30．吴方建．药物经济学理论及应用B(续)．2004年10月28日http://www.chzyy.com.cn.
31．陈民，李孜，何强等．肾替代治疗初期的成本-效用分析．中国循证医学杂志 2004，4(7)：453-459．
32．刘志涛，祁秉先，姜润生．成本效用分析原则及方法初探．卫生软科学，2003；17(5)：36-37．
33．熊敏，昊一龙 主编．现代肺癌病理与临床．科学出版社．2003．
34. Lilenbaum RC, Green MR. Multimodality therapy for non-small-cell lung cancer.Lung Oncology (USA).1994; 8: 25-31.
35. Bunn PA Jr. The treatment of non-small cell lung cancer: Current perspectives and controversies, future directions. Semin Oncol, 1994; 21(Suppl 6): 49-59.
36. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a Metaanalysis using updated data on individual patients from 52 randomised clinical trials.BMJ.1995; 311: 899-909.
37. The Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu Japan). A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study). Eur J Surg Oncol, 1995; 21(1): 69-77.
38. West Japan Study Group for lung cancer surgery (WJSG). Postoperative adjuvant chemotherapy with PVM (Cisplatin+Vindesine+Mitomycin C) and UFT (Uracil+Tegaful) in resected stage Ⅰ-Ⅱ NSCLC (non-small cell lung cancer): a randomized clinical trial. Eur J Cardiothorac Surg, 1999; 15(4): 438-443.
39．韩宝惠．早期非小细胞肺癌多学科治疗的争议．循证医学．2003，3(2)：68-69．
40．龚民，王天佑，田锋等．早期非小细胞肺癌的外科治疗．中华临床医药，2002；3(7)：20-21．
41. Maurizio Tonato. Final report of the (ALPI)-an Italian/ EORTC-LCG randomized trial of adjuvant chemotherapy in completely resected non-small cell lung cancer(NSCLC). Annals of Oncology; 13(Suppl.5): 9.
42. Scagliotti GV, Fossati R, Torri V, et al.Randomized study of adjuvant chemotherapy for completely resected stage Ⅰ, Ⅱ, or Ⅲa non-small-cell lung cancer.J Natl Cancer Inst, 2003; 95: 1453-1461.
43．吴一龙，杨学宁，杨衿记等．2002年临床肿瘤学重要文献解读．循证医学，2003；3(1)：7-14．
44．钱正子，王华庆．Ⅰ b-Ⅲa期非小细胞肺癌术后辅助化疗的进展．中国肿瘤临床，2004；31(24)：1428-1430．
45. Katsuyuki Hotta, Keitaro Matsuo, Hiroshi Ueoka, et al. Role of Adjuvant Chemotherapy in Patients With Resected Non-Small-Cell Lung Cancer: Reappraisal With a Meta-Analysis of Randomized Controlled Trials. Journal of. Clinical Oncology, 2004; 22(19): 3860-3867.
46．廖日强，吴一龙，杨学宁等．非小细胞肺癌完全切除术后含铂辅助化疗方案累积Meta分析．循证医学，2003；3(4)： 196-203．
47. ASCO 2003 annual Chicago: Chemotherapy improves survival after lung cancer surgery.
48．陆舜．非小细胞肺癌综合．中国癌症杂志，2005；8(1)：74-76．
49. ASCO 2003 annual Chicago Harubumi Kato, Oral Chemotherapy Drug Extends Survival in Patients with Stage 1 Lung Cancer.
50. Strauss G, Herndon J, Maddaus M, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage 1B non-small cell lung cancer(NSCLC): Report of Cancer and Leukemia Group B (CALGB)Protocol 9633. Proc Am Soc Clin Oncol, 2004; 23(supp1): 7019a.
51. WintonT, Livingston R, Johnson D, et al. A prospective randomized trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely rezected stage Ⅰ B and Ⅱ non-smsll cell lung cancer(NSCLC)Intergroup JBR. Proc Am Soc Clin Oncol, 2004; 23(supp10): 7018a.
52．程超，王震，张国淳．肺癌治疗之华山论剑．循证医，2004；4(4)：239-246．
53．韩宝惠．非小细胞肺癌治疗的循证医学新进展．上海医学，2005；28(6)：451-455．
54. Katsuyuki Hotta, Keitaro Matsuo, Hiroshi Ueoka, et al. Role of Adjuvant Chemotherapy in Patients With Resected Non-Small-Cell Lung Cancer: Reappraisal With a Meta-Analysis of Randomized Controlled Trials. J Clin Oncol, 2004; 22(19): 3860-3867.
55．杨学宁，昊一龙．美国NCCN临床指引介绍．循证医学，2002；2(4)：242．
56．杨学宁，廖日强，吴一龙等．NCCN非小细胞肺癌临床指引2004／2005版更新-循证医学，2004；4(4)：252-256．
57．王吉耀．循证医学与临床实践．科学出版社，2002：2-12．
58．李强．循证医学：临床证据的产生、评价与利用．科学出版社，2001：1-11．
59．唐可京，黄顺伟，谢灿茂．循证医学和临床研究的创造性思维．循证医学，2001；1(1)：47．
60．叶国经，肺癌早期诊断与外科治疗进展(下)，医学理论与实践， 1994，7(6)：1-3．
61．吴一龙．影响临床实践的肺癌研究．循证医学，2003；3(4)：193-195．
62．吴一龙．非小细胞肺癌综合治疗的再认识．循证医学，2004：4(4)：193-195．
63．韩宝惠．评论非小细胞肺癌完全切除术后含铂辅助化疗方案的累积Meta分析．循证医学．
64. Jeffrey B, Rubins. The progress of therapy with Non-small cell lung cancer. J RespirDis, 2003; 24(7): 315-321.
65．钟文昭．2003年10个引人关注的肿瘤临床试验．循证医学，2004；4(1)：6-8．
66．王坤，吴一龙．1ALT第一个证明非小细胞肺癌完全切除后辅助化疗能提高生存率的临床研究．循证医学，2004；4(2)：94-96．
67．于琳整理．2004中国肺癌高峰论坛访谈．循证医学，2004；4(2)：125-128．
68．许小幸，李定国，蔡全才等．肠易激综合征病人生活质量及其影响因素分析．青岛大学医学院学报，2005；41(2)：151-153．
69．傅小龙．放疗在非小细胞肺癌治疗中地位和研究进展．中国癌症杂志，2005；15(3)：217-223．
70．洪明晃．从姑息治疗想到临床决策．中华肿瘤杂志．2000，22(2)：157．
2．隆瑞．哈佛商学院管理法则全书．中国对外翻译出版公司，2001；4(2)：2004-2029．
3. Jerome P. Kassirer, Alan J Moskiwitz, Joseph Lau, etal. Decision analysis: a progress report. Annals of international medicine, 1987; 106(2): 275-291.
4．张大庆．临床决策：医学哲学研究的一个重要领域．医学与哲学，2004；25(12)：17-20．
5. EDDY, DM. Clinical Decision Making. Boston: Joncs and Bardctt Publishers, 1996.
6．李幼平 主编．循证医学．高等教育出版社，2003．
7. Munehisa Imaizumi and Study Group of Adjuvant Chemotherapy for Lung Cancer (Chub Japan). Postoperative adjuvant cisplatin, vindesin, plusuracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer. Lung Cancer, 2005; 49(1): 85-94.
8. Niiranen A, Niitamo-Korhonen S, Kouri M, et al. Adjuvant chemotherapy after radical surgery for non-small-cell lung cancer: a randomized study. J Clin Oncol, 1992; 10: 1927-1932.
9. Ohta M, Tsuchiya R, Shimoyama M, et al. Adjuvant chemotherapy for completely resected stage Ⅲ non-small cell lung cancer. Results of a randomized prospective study. J Thorac Cardiovasc Surg, 1993; 106(4): 703-708.
10. The Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan). A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study). Eur J Surg Oncol, 1995; 21(1): 69-77.
11. West Japan Study Group for lung cancer surgery (WJSG). Postoperative adjuvant chemotherapy with PVM (Cisplatin+Vindesine+Mitomycin C) and UFT (Uracil+Tegaful) in resected stage Ⅰ-Ⅱ NSCLC (non-small cell lung cancer): a randomized clinical trial. Eur J Cardiothorac Surg, 1999; 15(4): 438-443.
12. Xu G, Rong T, Lin P.Adjuvant chemotherapy following radical surgery for non-small-cell lung cancer: a randomized study on 70 patients. Chin Med J (Engl), 2000; 113(7): 617-620.
13. Mineo TC, Ambrogi V, Corsaro V, et al. Postoperative adjuvant therapy for stage IB non-small-cell lung cancer. Eur J Cardiothorac Surg, 2001; 20(2): 378-884.
14. Tada H, Tsuchiya R, Ichinose Y, et al. Randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304). Lung Cancer, 2004; 43(2): 167-173.
15. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med, 2005; 352(25): 2589-2597.
16. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cance: a Meta-analysis using updated data on individual patients from 52 randomised clinical trials.BMJ.1995; 311: 899-909.
17. Katsuyuki Hotta, Keitaro Matsuo, Hiroshi Ueoka, et al. Role of Adjuvant Chemotherapy in Patients With Resected Non-Small-Cell Lung Cancer: Reappraisal With a Meta-Analysis of Randomized Controlled Trials. J Clin Oncol, 22(19); 2004: 3860-3867.
18．廖日强，吴一龙，杨学宁等．非小细胞肺癌完全切除术后含铂辅助化疗方案累积Meta分析．循证医学，2003；3(4)：196-203．
19. Van Houtte P, Rocmans P, Smets P, et al. Postoperative radiation therapy in lung caner: a controlled trial after resection of curative design. Int J Radiat Oncol Biol Phys, 1980; 6(8): 983-986.
20. Weisenburger TH. Effects of postoperative mediastinal radiation on completely resected stage Ⅱ and stage Ⅲ epidermoid cancer of the lung. LCSG 773.Chest, 1994; 106(6 Suppl): 297S-301S.
21. Debevec M, Bitenc M, Vidmar S, et al. Postoperative radiotherapy for radically resected N2 non-small-cell lung cancer (NSCLC): randomised clinical study 1988-1992. Lung Cancer, 1996; 14(1): 99-107.
22. Lafitte JJ, Ribet ME, Prevost BM, et al. Postresection irradiation for T2 NO MO non-small cell carcinoma: a prospective, randomized study. Ann Thorac Surg, 1996; 62(3): 830-834.
23. Stephens RJ, Girling DJ, Bleehen NM, et al. Amulticentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Br J Cancer, 1996; 74(4): 632-639.
24. Dautzenberg B, Arriagada R, Chammard AB, et al. A controlled study of postoperative radiotherapy for patients with completely resected non-small cell lung carcinoma. Groupe d'Etude et de Traitement des Cancers Bronchiques. Cancer, 1999; 86(2): 265-273.
25. Feng QF, Wang M, Wang LJ, et al. A study of postoperative radiotherapy in patients with non-small-cell lung cancer: a randomized trial. J Radiat Oncol Biol Phys, 2000; 47(4): 925-9.
26．曹卡加，黄惠英，练小荷，崔念基．Ⅲa(N2)期非小细胞肺癌术后放疗的疗效评价．癌症，2001，20(3)：305-307．
27．姚波，周大明，程玉龙等．非小细胞肺癌术后放疗的临床意义．黑龙江医学，2001， 25(11)：808-809．
28. Trodella L, Granone P, Valente S, et al. Adjuvant radiotherapy in non-small cell lung cancer with pathological stage Ⅰ: definitive results of a phase Ⅲ randomized trial. Radiother Oncol, 2002; 62(1): 11-29.
29．曹卡加，黄惠英，练小荷等．术后放射治疗对非小细胞肺癌疗 效的影响．中国肿瘤,2003；30(9)：642—644．
30. PORT Meta-analysis Trialists Group.Postoperative radiotherapy in non-small-cell lung cancer: systematic review and Meta-analysis of individual patient data from nine randomised controlled trials. Lancet, 1998; 352(9124): 257-263.
31. Burdett S, Stewart L; on behalf of the PORT Meta-analysis Group. Postoperative radiotherapy in non-small-cell lung cancer: update of an individual patient data Meta-analysis. Lung Cancer. 2005 Jan; 47(1): 81-83.
32. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst, 1996 Sep 4; 88(17): 1210-1215.
33. Dautzenberg B, Chastang C, Arriagada R, et al. Adjuvant radiotherapy versus combined sequential chemotherapy followed by radiotherapy in the treatment of resected nonsmall cell lung carcinoma. A randomized trial of 267 patients. GETCB (Groupe d'Etude et de Traitement des Cancers Bronchiques). Cancer, 1995 Sep 1; 76(5): 779-786.
34. Steven M. Keller, M.D., SudeshnaAdak, Ph.D. et al. for The Eastern Cooperative Oncology Group.ARandomized Trial of Postoperative Adjuvant Therapy in Patients with Completely Resected Stage II or IIIa Non-Small-Cell Lung Cancer. J Clin Oncol, 2000; 343(17): 1217-1222.
35. Lad T. The comparison of CAP chemotherapy and radiotherapy to radiotherapy alone for resected lung cancer with positive margin or involved highest sampled para- tracheal node (stage IIIA). LCSG 791. Chest, 1994 Dec; 106(6 Suppl): 302S-306S.
36. Ovac V, Smrdel U, Institute of Oncology. Meta-analyses of clinical trials in patients with non-small cell lung cancer. Neoplasm, 2004; 51(5): 334-340.
37. Maurizio Tonato. Final report of the (ALPI)-an Italian/ EORTC-LCG randomized trial of adjuvant chemotherapy in completely resected non-small cell lung cancer(NSCLC). Annals of Oncology, 13(Suppl.5): 9.
38. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage Ⅰ, Ⅱ, or Ⅲa non-small-cell lung cancer. J Natl Cancer Inst, 2003; 95: 1453-1461.
39．吴一龙，杨学宁，杨衿记等．2002年临床肿瘤学重要文献解读．循证医学，2003；3(1)：7-14．
40．钱正子，王华庆．Ⅰb-Ⅲa期非小细胞肺癌术后辅助化疗的进展．中国肿瘤临床，2004；31(24)：1428-1430。
41. ASCO 2003 annual Chicago: Chemotherapy improves survival after lung cancer surgery.
42．陆舜．非小细胞肺癌综合．中国癌症杂志，2005；8(1)：74-76．
43. Strauss G, Herndon J, Maddaus M, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage 1B non-small cell lung cancer(NSCLC): Report of Cancer and Leukemia Group B (CALGB)Protocol 9633. Proc Am Soc Clin Oncol, 2004; 23(supp1): 7019a.
44. Winton T, Livingston R, Johnson D, et al. A prospective randomized trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely rezected stage Ⅰ B and Ⅱ non-smsll cell lung cancer(NSCLC) Intergroup JBR. Proc Am Soc Clin Oncol, 2004; 23(supp10): 7018a.
45．韩宝惠．早期非小细胞肺癌多学科治疗的争议．循证医学，2003；3(2)：68-69．
46．夏佳，李晓松．非小细胞肺癌完全切除术后含铂辅助化疗效果的Meta分析．中国循证医学杂志，2005；5(12)：936-940．
47．傅小龙．放疗在非小细胞肺癌治疗中地位和研究进展．中国癌症杂志，2005；15(3)：217-223．
48．姜丽萍，瞿佳．循证医学在眼视光学的应用(Ⅲ)临床决策分析． 眼视光学杂志，2002；4(3)：185-186．
49．吴久鸿，刘国恩．药物经济学在我国的发展现状及应用．中国药物应用与监测，2005；1：1-4．
50．文朝阳，洪明晃．临床科学研究-设计、测量、评价．生存质量的测量与评价第2版，中山大学出版社，2002：62-77．
51．谢忠，潘达超，廖思海等．干扰素甲地孕图配合EP方案与单纯E防案治疗晚期非小细胞肺癌的对比研究．癌症，2000；19(4)： 370-373．
52．刘志涛，祁秉先，姜润生．成本效用分析原则及方法初探．卫生软科学，2003；17(5)：36-37．
53．陈民，李孜，何强等．肾替代治疗初期的成本-效用分析．中国循证医学杂志 2004，4(7)：453-459．
54. Desch CE, Lasala MR, Smith TJ, et al. The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse. J Clin Oncol, 1992Feb; 10(2): 200-209.
55. Wilcox GM, Beck JR. Early invasive cancer in adenomatous colonic polyps ("malignant polyps"). Evaluation of the therapeutic options by decision analysis.Gastroenterology, 1987 May; 92: 1159-1168.
56. Plante DA, Piccirillo JF, Sofferman RA. Decision analysis of treatment options in pyriform sinus carcinoma. Med Decis Making, 1987A; 7(2): 74-83.
57. Velanovich V. Choice of treatment for stage 1 floor-of-mouth cancer. A decision analysis. Arch Otolaryngol Head Neck Surg, 1990; 116: 951-956.
58. MD Brundage, PA Groome, D Feldman-Stewart, et al. Decision analysis in locally advanced non-small cell lung cancer: is it useful? J Clin Oncol, 1997: 873-883.
59. Hillner BE, Smith TJ. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med, 1991; 324(3): 160-168.
60. Fleming C, Wasson JH, Albertsen PC, et al. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. JAMA, 1993 26; 269(20): 2650-2658.
61. Mold JW, Holtgrave DR, Bisonni RS, et al. The evaluation and treatment of men with asymptomatic prostate nodules in primary care: a decision analysis.J Fam Pract, 1992; 34(5): 561-568.
62．朱彩蓉．糖尿病治疗效果的药物经济学研究．四川大学博士学位论文．2004．
63．陈洁．药物经济．成都科技大学出版社，2000．
64．孙利华．药物经济学与新药研究发展．化学工业出版社，2003．
65．张新平．测量健康状况的新指标-QALYs．国外医学社会医学分册，1997；14(1)：22-24．
66．熊敏，吴一龙 主编．现代肺癌病理与临床．科学出版社．2003．
67．杨学宁，廖日强，吴一龙等．NCCN非小细胞肺癌临床指引2004/2005版更新．循证医学，2004；4(4)：252-256．
68．于琳 整理．2004中国肺癌高峰论坛访谈．循证医学．2004，4(2)：125-128．
69. Jeffrey B, Rubins. The progress of therapy with Non-small cell lung cancer. J Respir Dis, 2003; 24(7): 315-321.
70．许小幸，李定国，蔡全才等．肠易激综合征病人生活质量及其影响因素分析．青岛大学医学院学报，2005；41(2)：151-153．
71．孙晓花，刘爱忠．应用Markov模型进行临床决策分析的思考．医学与哲学，2004；25(8)：8-9．
1．席酉民．管理研究．机械工业出版社，2000：328-339．
2．隆瑞．哈佛商学院管理法则全书．中国对外翻译出版公司，2001：2004-2029．
3．陈铤．决策分析．科技出版社，1987．
4．刘文龙，高爱厚．经济决策分析．军事谊文出版社，1993．
5．姜青舫．实用决策分析．贵州人民出版社，1988．
6．张斌等．市场预测与决策．电子科技大学出版社，1996．
7. Jerome P. Kassirer, Alan J Moskiwitz, Joseph Lau, et al. Decision analysis: a progress report. Annals of international medicine, 1987; 106(2): 275-291.
8．张大庆．临床决策：医学哲学研究的一个重要领域．医学与哲学，2004；25(12)：17-20．
9. Eddy DM. Clinical Decision Making. Boston: Joncs and Bardctt Publishers. 1996.
10．李幼平 主编．循证医学．高等教育出版社．2003．
11．姜丽萍，瞿佳．循证医学在眼视光学的应用(Ⅲ)临床决策分析．眼视光学杂志，2002；4(3)：185-186．
12．史宗道．循证医学与临床决策分析．辽宁医学杂志，2001；15(5)： 229-233．
13．《默克诊疗手册》第二十一章，特殊医学．第295节．临床决策．用Bayes定理修正概率．
14．顾维正，马静波，杨滔波等．临床甲状腺功能检查新策略的医学决策学方法初步探讨．科技通报，1995；11(6)：375-380．
15．孙晓花，刘爱忠．应用Markov模型进行临床决策分析的思考．医学与哲学， 2004；25(8)：8-9，20．
16．王倩．应用Markov模型进行临床决策分析．《国外医学》卫生经济分册，2000；17(2)：89-90．
17. Hillner BE, Smith TJ. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med, 1991; 324(3): 160-8.
18. Fleming C, Wasson JH, Albertsen PC, et aI. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. JAMA, 1993; 269(20): 2650-2658.
19. Mold JW, Holtgrave DR, Bisonni RS, et al. The evaluation and treatment of men with asymptomatic prostate nodules in primary care: a decision analysis. J Fam Pract, 1992; 34(5): 561-568.
20．徐凌中，柳丽华，王永杰．效用指标的测量方法及其研究进展．国外医学卫生经济分册，2001；18(2)：88-92．
21．朱彩蓉．糖尿病治疗效果的药物经济学研究．四川大学博士学位论文．2004．
22．陈洁．药物经济．成都科技大学出版社，2000．
23．孙利华．药物经济学与新药研究发展．化学工业出版社，2003．
24．吴久鸿，刘国恩．药物经济学在我国的发展现状及应用前．中国药物应用与监测，2005；1：1-4．
25．文朝阳．生存质量的测量与评价．临床科学研究-设计、测量、评价冲山大学出版社，2002：62-77．
26．杨宁德，李凌江，陈晋东．生活质量评估外科手术医师临床决策的新思考．当代医师杂志，1998；3(9)：47-49．
27．杨朋，吴一龙，谷力加．评估肺癌患者生活质量的方法学．循证医学，2002；2(2)：105-107．
28．王卫华，卢祖洵．生命质量研究的现状与趋势．医学与社会，2005； 18(7)： 8-10．
29．谢忠，潘达超，廖思海等．干扰素甲地孕图配合EP方案与单纯E防案治疗晚期非小细胞肺癌的对比研究．癌症，2000； 19(4)：370-373．
30．吴方建．药物经济学理论及应用B(续)．2004年10月28日http://www.chzyy.com.cn.
31．陈民，李孜，何强等．肾替代治疗初期的成本-效用分析．中国循证医学杂志 2004，4(7)：453-459．
32．刘志涛，祁秉先，姜润生．成本效用分析原则及方法初探．卫生软科学，2003；17(5)：36-37．
33．熊敏，昊一龙 主编．现代肺癌病理与临床．科学出版社．2003．
34. Lilenbaum RC, Green MR. Multimodality therapy for non-small-cell lung cancer.Lung Oncology (USA).1994; 8: 25-31.
35. Bunn PA Jr. The treatment of non-small cell lung cancer: Current perspectives and controversies, future directions. Semin Oncol, 1994; 21(Suppl 6): 49-59.
36. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a Metaanalysis using updated data on individual patients from 52 randomised clinical trials.BMJ.1995; 311: 899-909.
37. The Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu Japan). A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study). Eur J Surg Oncol, 1995; 21(1): 69-77.
38. West Japan Study Group for lung cancer surgery (WJSG). Postoperative adjuvant chemotherapy with PVM (Cisplatin+Vindesine+Mitomycin C) and UFT (Uracil+Tegaful) in resected stage Ⅰ-Ⅱ NSCLC (non-small cell lung cancer): a randomized clinical trial. Eur J Cardiothorac Surg, 1999; 15(4): 438-443.
39．韩宝惠．早期非小细胞肺癌多学科治疗的争议．循证医学．2003，3(2)：68-69．
40．龚民，王天佑，田锋等．早期非小细胞肺癌的外科治疗．中华临床医药，2002；3(7)：20-21．
41. Maurizio Tonato. Final report of the (ALPI)-an Italian/ EORTC-LCG randomized trial of adjuvant chemotherapy in completely resected non-small cell lung cancer(NSCLC). Annals of Oncology; 13(Suppl.5): 9.
42. Scagliotti GV, Fossati R, Torri V, et al.Randomized study of adjuvant chemotherapy for completely resected stage Ⅰ, Ⅱ, or Ⅲa non-small-cell lung cancer.J Natl Cancer Inst, 2003; 95: 1453-1461.
43．吴一龙，杨学宁，杨衿记等．2002年临床肿瘤学重要文献解读．循证医学，2003；3(1)：7-14．
44．钱正子，王华庆．Ⅰ b-Ⅲa期非小细胞肺癌术后辅助化疗的进展．中国肿瘤临床，2004；31(24)：1428-1430．
45. Katsuyuki Hotta, Keitaro Matsuo, Hiroshi Ueoka, et al. Role of Adjuvant Chemotherapy in Patients With Resected Non-Small-Cell Lung Cancer: Reappraisal With a Meta-Analysis of Randomized Controlled Trials. Journal of. Clinical Oncology, 2004; 22(19): 3860-3867.
46．廖日强，吴一龙，杨学宁等．非小细胞肺癌完全切除术后含铂辅助化疗方案累积Meta分析．循证医学，2003；3(4)： 196-203．
47. ASCO 2003 annual Chicago: Chemotherapy improves survival after lung cancer surgery.
48．陆舜．非小细胞肺癌综合．中国癌症杂志，2005；8(1)：74-76．
49. ASCO 2003 annual Chicago Harubumi Kato, Oral Chemotherapy Drug Extends Survival in Patients with Stage 1 Lung Cancer.
50. Strauss G, Herndon J, Maddaus M, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage 1B non-small cell lung cancer(NSCLC): Report of Cancer and Leukemia Group B (CALGB)Protocol 9633. Proc Am Soc Clin Oncol, 2004; 23(supp1): 7019a.
51. WintonT, Livingston R, Johnson D, et al. A prospective randomized trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely rezected stage Ⅰ B and Ⅱ non-smsll cell lung cancer(NSCLC)Intergroup JBR. Proc Am Soc Clin Oncol, 2004; 23(supp10): 7018a.
52．程超，王震，张国淳．肺癌治疗之华山论剑．循证医，2004；4(4)：239-246．
53．韩宝惠．非小细胞肺癌治疗的循证医学新进展．上海医学，2005；28(6)：451-455．
54. Katsuyuki Hotta, Keitaro Matsuo, Hiroshi Ueoka, et al. Role of Adjuvant Chemotherapy in Patients With Resected Non-Small-Cell Lung Cancer: Reappraisal With a Meta-Analysis of Randomized Controlled Trials. J Clin Oncol, 2004; 22(19): 3860-3867.
55．杨学宁，昊一龙．美国NCCN临床指引介绍．循证医学，2002；2(4)：242．
56．杨学宁，廖日强，吴一龙等．NCCN非小细胞肺癌临床指引2004／2005版更新-循证医学，2004；4(4)：252-256．
57．王吉耀．循证医学与临床实践．科学出版社，2002：2-12．
58．李强．循证医学：临床证据的产生、评价与利用．科学出版社，2001：1-11．
59．唐可京，黄顺伟，谢灿茂．循证医学和临床研究的创造性思维．循证医学，2001；1(1)：47．
60．叶国经，肺癌早期诊断与外科治疗进展(下)，医学理论与实践， 1994，7(6)：1-3．
61．吴一龙．影响临床实践的肺癌研究．循证医学，2003；3(4)：193-195．
62．吴一龙．非小细胞肺癌综合治疗的再认识．循证医学，2004：4(4)：193-195．
63．韩宝惠．评论非小细胞肺癌完全切除术后含铂辅助化疗方案的累积Meta分析．循证医学．
64. Jeffrey B, Rubins. The progress of therapy with Non-small cell lung cancer. J RespirDis, 2003; 24(7): 315-321.
65．钟文昭．2003年10个引人关注的肿瘤临床试验．循证医学，2004；4(1)：6-8．
66．王坤，吴一龙．1ALT第一个证明非小细胞肺癌完全切除后辅助化疗能提高生存率的临床研究．循证医学，2004；4(2)：94-96．
67．于琳整理．2004中国肺癌高峰论坛访谈．循证医学，2004；4(2)：125-128．
68．许小幸，李定国，蔡全才等．肠易激综合征病人生活质量及其影响因素分析．青岛大学医学院学报，2005；41(2)：151-153．
69．傅小龙．放疗在非小细胞肺癌治疗中地位和研究进展．中国癌症杂志，2005；15(3)：217-223．
70．洪明晃．从姑息治疗想到临床决策．中华肿瘤杂志．2000，22(2)：157．